Alt
/content/dam/asset-migration/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Dr Mike Fay.jpg

Dr Mike Fay

Dr Mike Fay
MBChB, FRACP, FRANZCR, PhD, Radiation Oncologist

Expanding treatment options for patients with resistant and hard to treat cancers is my passion and mission.

Languages spoken

English

Overview

Centres

Newcastle (Oncology)
Newcastle (Oncology)
-32.98074188217417, 151.69224925942373
/au/our-centres/newcastle
Maitland (Oncology)
Maitland (Oncology)
-32.76007886629645, 151.60103195567942
/au/our-centres/maitland-oncology

Treatments

Palliative radiation therapy
Service
Service/Cancer
Service/Cancer/Radiation Oncology
Service/Cancer/Radiation Oncology/Palliative Radiation Therapy
Radiation therapy
Service
Service/Cancer
Service/Cancer/Radiation Oncology
Service/Cancer/Radiation Oncology/Radiation Therapy

Specialises in

Brain & spine cancer
Condition
Condition/Cancer
Condition/Cancer/Brain and Spine Cancer
Gastrointestinal cancer
Condition
Condition/Cancer
Condition/Cancer/Gastrointestinal Cancer
Lung cancer
Condition
Condition/Cancer
Condition/Cancer/Lung Cancer
Skin cancer
Condition
Condition/Cancer
Condition/Cancer/Skin Cancer

Special clinical interest in theranostics, gastrointestinal, skin, lung, neuro-oncology, palliative care, and stereotactic radiosurgery.

Dr Fay trained in medical oncology and moved to radiation oncology with research interests in lung and neuro-oncology. Dr Fay completed his undergraduate degree in Medicine and Surgery at University of Otago and completed his PhD on integration of advanced images into brain tumour treatment. He has worked in 36 hospitals across five countries, including the US, Germany, UK, New Zealand and Australia. Dr Fay is also the Chief Medical Officer at AdvanCell Isotopes.

Awards

  • Funded by the Mark Hughes Foundation, Dr Fay was named as the inaugural recipient of a three-year HMRI Mid-Career Research Fellowship dedicated to brain cancer.

 

  • Dr Fay won a prize from the Royal Australian and New Zealand College of Radiologists for his research study on predicting toxicity from radiotherapy which was published in the International Journal of Radiation Oncology Biology and Physics.

Research interests

  • Dr Fay’s research interests include lung and neuro-oncology with a focus on brain tumours and the development of new imaging and treatment techniques. He is the principal investigator in a number of international cancer trials and collaborations with Canada, the UK and Germany. His research spans across several modalities including PET imagery, MRI imaging and developing multiplexed neuro-imaging techniques. As well as securing over $4.5m in research funding over the last ten years, he is a lead researcher in an NCIC trial into brain tumour treatment in elderly patients.
  • Dr Fay is fascinated by how PET imaging has revolutionised oncology care in the past 20 years and is set to revolutionise therapy in the development of theranostics. A current research project centres on developing a new PET tracer for use in brain tumours. Dr Fay is looking forward to using new imaging tools to better understand treatment resistant mechanisms and optimise brain cancer treatments.

Professional memberships

  • Dr Fay is a member of ASCO, ASTRO and COGNO and on the editorial board of The Journal of Translational Lung Cancer Research.

Publications

  • DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets. Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay & Paul A. Tooney. Cellular Oncology (2021). Read here.
  • Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. James R. Perry, M.D., Normand Laperriere, M.D., Christopher J. O’Callaghan, D.V.M., Alba A. Brandes, M.D., Johan Menten, M.D., Claire Phillips, M.B., B.S., Michael Fay, M.B., Ch.B., Ryo Nishikawa, M.D., J. Gregory Cairncross, M.D., Wilson Roa, M.D., David Osoba, M.D., John P. Rossiter, M.B., B.Ch., et al., for the Trial Investigators. The New England Journal of Medicine (March 2017) Read here.
  • R. J. Head, M. F. Fay, L. Cosgrove, K. Y. C. Fung, D. Rundle-Thiele & J. H. Martin (2017) Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma, Cancer Biology & Therapy, 18:12, 917-926, Read here.
  • Valproate in Adjuvant Glioblastoma Treatment. DOI: 10.1200/JCO.2016.67.2162  Journal of Clinical Oncology 34, no. 25 (September 01, 2016) 3105-3107. Published online June 13, 2016. PMID: 2729840
  • PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Simon Puttick, Christopher Bell, Nicholas Dowson, Stephen Rose, Michael Fay. Read here.